Mengke Pharmaceutical (688373.SH) announced that the company submitted MRs for injectable use in European countries and Latin American countries...
According to the Zhitong Finance App, Mengke Pharmaceutical (688373.SH) announced that the company's drug clinical trial applications for injectable MRX-4 sequential contizolamide tablets for diabetic foot infections submitted by the company in European countries and Latin American countries have been approved by 5 additional countries, allowing clinical trials to be carried out in the UK, Turkey, Georgia, Argentina and Chile.